Bioequivalence and Bioavailability Forum 03:17 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Full-replicate design in two groups [General Sta­tis­tics]

posted by Mikalai - Belarus, 2018-10-31 14:04  - Posting: # 19510
Views: 438

Dear all,
We are conducting a full replicate design study. Due to recruiting difficulties we had to split the study in two groups. It has been suggested that we should change our statistical model to model II of FDA. What risks, if any, carry on this model to our bioequivalence? Can additional factors in model artificially reduce our CV and push us out of the scaled approach to usual 125%-80% one (I am not a statistician, so my question may be statistically correct)? Should we change our usual 4-factor model?

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,037 posts in 4,061 threads, 1,300 registered users;
online 11 (0 registered, 11 guests [including 8 identified bots]).

An expert is a man who has made all the mistakes,
which can be made, in a very narrow field.    Niels Bohr

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed